Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug [Seeking Alpha]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Seeking Alpha
Despite positive Phase 3 data, the FDA unexpectedly rejected CORT's NDA for Relacorilant, citing insufficient benefit-risk evidence. Korlym's ongoing revenues provide a valuation floor and financial support for further Relacorilant trials. CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval. Wirestock/iStock via Getty Images Corcept Therapeutics Overview Corcept Therapeutics is a commercial-stage biotech company that is focused on finding treatments for the modulation of cortisol, a hormone related to Cushing's Syndrome. Since 2012, the Company has marketed Korlym as a treatment for This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens BermanGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORTPR Newswire
- Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts? [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics (NASDAQ:CORT) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law FirmPR Newswire
CORT
Earnings
- 11/4/25 - Miss
CORT
Sec Filings
- 1/8/26 - Form 4
- 1/6/26 - Form 144
- 1/5/26 - Form 4
- CORT's page on the SEC website